Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

• ClinicalTrials.gov Identifier: NCT04813562
• Recruitment Status: Recruiting
• First Posted: March 24, 2021
• Last Update Posted: March 24, 2021
• Sponsor: Jiangsu Province Centers for Disease Control and Prevention
• Collaborator: Academy of Military Medical Sciences，Academy of Military Sciences，PLA ZHONGYIANKE Biotech Co, Ltd. LIAONINGMAOKANGYUAN Biotech Co, Ltd
• Information provided by (Responsible Party): Jiangsu Province Centers for Disease Control and Prevention

Study Description

Brief Summary:

This is a phase Ⅱ, randomized, placebo-controlled, double-blind study, to evaluate immunogenicity and safety of a recombinant COVID-19 vaccine (CHO cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) with an immunization procedure (0, 28, 56 days).

Condition or disease	Intervention/treatment	Phase
COVID-19	Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56; Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56; Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56; Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56; Biological: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56; Biological: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56; Biological: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56; Biological: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56	Phase 2

Detailed Description:

This is a phase Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (CHO cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) . The phase Ⅱ clinical trials designed 4 research group, including an immunization procedures (0, 28, 56 days), two doses (20μg/0.5ml, 40μg/0.5ml) and two ages group (adults and elder): Each group including 120 participants. Vaccination or placebo group will be randomly assigned to receive in a 5:1 ratio, 480 in total.

Cellular immune blood samples were collected from the top 96 subjects (i.e., the top 24 in each study group, vaccine group: control group =5:1), and Elispot test and cytokine staining (ICS)/flow assay were performed.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 480 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Prevention
• Official Title: A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above
• Estimated Study Start Date: March 23, 2021
• Estimated Primary Completion Date: July 30, 2021
• Estimated Study Completion Date: June 30, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Middle-dose vaccine (18-59 years); Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56	Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56; 18-59 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
Experimental: High-dose vaccine (18-59 years); Two doses of High-dose vaccine at the schedule of day 0, 28, 56	Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56; 18-59 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
Experimental: Middle-dose vaccine (60-85 years); Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56	Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56; 60-85 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
Experimental: High-dose vaccine (60-85 years); Two doses of High-dose experimental vaccine at the schedule of day 0, 28, 56	Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56; 60-85 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
Placebo Comparator: Middle-dose placebo (18-59 years); Three doses of middle-dose placebo at the schedule of day 0, 28, 56	Biological: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56; 18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
Placebo Comparator: High-dose placebo (18-59 years); Two doses of High-dose placebo at the schedule of day 0, 28, 56	Biological: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56; 18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
Placebo Comparator: Middle-dose placebo (60-85 years); Three doses of middle-dose placebo at the schedule of day 0, 28, 56	Biological: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56; 60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
Placebo Comparator: High-dose placebo (60-85 years); Two doses of High-dose placebo at the schedule of day 0, 28, 56	Biological: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56; 60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.

Outcome Measures

Primary Outcome Measures :

1. The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (eucivirus neutralization assays) [ Time Frame: 30 days after full-course vaccination in each study group ]
2. The incidence of adverse reaction (AR) [ Time Frame: 0 to 7 days after vaccination in each study group ]

Secondary Outcome Measures :

1. The incidence of adverse events (AE) [ Time Frame: 0 to 30 days after vaccination in each study group ]
2. The incidence of severe adverse events (SAE) [ Time Frame: 12 months after prime and boost vaccination ]
3. The Geometric mean titer (GMT) of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization assays) [ Time Frame: 14 days, 30 days, 6 months and 12 months after full-course vaccination in each study group ]
4. The Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization assays) [ Time Frame: 14 days, 30 days, 6 months and 12 months after full-course vaccination in each study group ]
5. The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (eucivirus neutralization assays) [ Time Frame: 14 days, 6 months and 12 months after full-course vaccination in each study group ]
6. The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (pseudovirus neutralization assays) [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]
7. The positive conversion rate of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]
8. The GMT of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]
9. The GMI of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]

Other Outcome Measures:

1. The geometric mean titer (GMT) ratio of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody in each study groups [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]
2. Subtypes of IgG antibodies against the S-RBD protein of SARS-CoV-2 after immunization in each study group [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]
3. The proportion of IFN-γ secreted by T cells at Day 14 using ELISpot detection method [ Time Frame: Day 14 after full-course vaccination in each study group ]
4. The Intracellular cytokine staining (ICS)/flow cytometry was used to detect the Th1/Th2 immune response after immunization (CD3+/CD4+/CD8+ T cells, and cytokines TNFα/IFNγ/IL2/IL4). [ Time Frame: Day 14 after full-course vaccination in each study group ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 85 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Healthy subjects of ≥ 18 years old.
• The subject can understand and voluntarily sign the informed consent.
• Axillary temperature ≤37.0℃.
• General good health as established by medical history and physical examination

Exclusion Criteria:

• Have a history of close contact with a confirmed case of SARS-CoV-2, an asymptomatic infection in the previous 14 days, or a travel history/residential history in a community where a case has been reported.
• Have a history of contact with a person infected with SARS-CoV-2(a person with a positive nucleic acid test) in the previous 14 days.
• Patients with fever or respiratory symptoms who have been to middle or high-risk areas in the past 14 days or have exit history, or come from communities with case reports.
• In the past 14 days, there have been 2 or more cases of fever and/or respiratory symptoms in small areas such as homes, offices, school classes, etc.
• Have a history of SARS.
• Have a history of SARS-CoV-2 infection or history of Coronavirus Vaccination (including Emergency Vaccine and Experimental Vaccine).
• Positive in SARS-CoV-2 IgG or IgM antibody screening.
• Have a history of HIV infection;
• Women who are breastfeeding, pregnant, or planning to become pregnant during 6 months after full-course vaccination (based on the subject's self-report and blood pregnancy test results for women of childbearing age).
• Have a history of asthma, a history of vaccine or vaccine component allergy, have serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema.
• Subjects with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
• Subjects with autoimmune diseases or immunodeficiency/immunosuppression.
• Subjects with severe chronic diseases, severe cardiovascular diseases, hypertension(sbp≥160mmHg and/or dbp≥100mmHg) and diabetes that cannot be controlled by drugs, liver and kidney diseases, malignant tumors, etc.
• Subjects with severe neurological disease (epilepsy, convulsions or convulsions) or mental illness.
• Subjects with thyroid disease or history of thyroidectomy, no spleen, functional asthenia, and any spleen or splenectomy caused by any condition.
• Abnormal blood coagulation function diagnosed by a doctor (such as coagulation factor deficiency, coagulopathy, abnormal platelet) or obvious bruise or coagulation disorder.
• Have received immunosuppressant therapy, cytotoxic therapy, and inhaled corticosteroids in the past 6 months (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-complicated dermatitis).
• Received blood products within 3 months before receiving trial vaccine.
• Received other study drugs within 30 days before receiving the trail vaccine.
• Received a live attenuated vaccine within 14 days before receiving the experimental vaccine.
• Received a subunit or inactivated vaccine within 7 days before receiving the experimental vaccine.
• Various acute or chronic diseases occurred in the past 7 days.
• Have a long history of alcohol or drug abuse.
• Had urticaria one year before receiving the experimental vaccine;
• congenital or acquired angioedema/neuroedema;
• According to the judgment of the investigator, the subject has any other factors that are not suitable for participating in the clinical trial, or Or influence the subject to sign the informed consent.

Exclusion criteria of subsequent dose:

• Patients with severe allergic reactions after the previous dose of vaccination;
• Patients with serious adverse reactions causally related to the previous dose of vaccination.
• For those newly discovered or newly discovered after the first vaccination that does not meet the first-dose selection criteria or meets the first-dose exclusion criteria, the investigator will determine whether to continue participating in the study.
• Other exclusion reasons suggested by the researchers.

Contacts and Locations

Contacts

Contact: Fanyue Meng, Doctor; 18915999245; mfy19780712@163.com

Locations

China, Jiangsu

Jiangsu Provincial Center for Diseases Control and Prevention; Recruiting

Nanjing, Jiangsu, China

Contact: Mingwei Wei 15950529760 wnmcwmw@163.com

Sponsors and Collaborators

Jiangsu Province Centers for Disease Control and Prevention

Academy of Military Medical Sciences，Academy of Military Sciences，PLA ZHONGYIANKE Biotech Co, Ltd. LIAONINGMAOKANGYUAN Biotech Co, Ltd

Investigators

• Principal Investigator: Fengcai Zhu, Doctor; Jiangsu Provincial Center for Disease Control and Prevention

More Information

• Responsible Party: Jiangsu Province Centers for Disease Control and Prevention
• ClinicalTrials.gov Identifier: NCT04813562
• Other Study ID Numbers: JSVCT097
• First Posted: March 24, 2021
• Last Update Posted: March 24, 2021
• Last Verified: March 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jiangsu Province Centers for Disease Control and Prevention:

Immunogenicity; Safety; COVID-19 vaccine; Recombinant vaccine

Additional relevant MeSH terms:

Vaccines; Immunologic Factors; Physiological Effects of Drugs